Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A

Cocrystal Pharma Inc COCP announced that CC-42344 demonstrated a favorable safety profile in the single-ascending and multiple-ascending dose portions of the ongoing Phase 1 study.
CC-42344 is a broad-spectrum oral antiviral for pandemic and seasonal influenza A.
The randomized, double-controlled, dose-escalating Phase 1 study in Australia was designed to assess the safety, tolerability, and pharmacokinetics (PK) of orally administered CC-42344 in healthy adults.
Related: Cocrystal Pharma Advances One Of Its COVID-19 Antiviral Treatment Candidate.
In July 2022, Cocrystal reported that PK data from the single-ascending dose portion of the study supported once-daily dosing.
In October 2022, enrollment in the multiple-ascending dose portion of the trial was completed.
The company plans to present topline study results at the upcoming World Antiviral Congress on December 1 and submit an application with the United Kingdom Medicines and Healthcare Products Regulatory Agency to conduct a Phase 2a human challenge study in early 2023.
Subject to regulatory agency clearance, the Phase 2a study is expected to be initiated in the second half of 2023.
Price Action: COCP shares are up 2.49% at $3.07 on the last check Thursday.